Inhibrx, Inc. revenue decreases to $17,000 in quarter ended Mar 31, 2023 from previous quarter
Key fundamental financials
loss of $48.92 million
Revenue of $17,000
Current Reporting
Revenue
Net Income
Profit/Loss
Mar 2023
$17,000
$48.92 million
loss
Sep 2022
$278
$35,325
loss
Jun 2022
$711,000
$37.73 million
loss
Inhibrx, Inc. [INBX] has reported $48.92 million loss for the fiscal quarter ending Mar 31, 2023.
Revenue for the quarter was $17,000 with operating income of $43.77 million.
The Lajolla, California (CA)-based company operating in the biological products, except diagnostic substances sector has total shareholders equity of $15.13 million.